Alerts will be sent to your verified email
Verify Email
LYKALABS
|
Lyka Labs
|
Trident Lifeline
|
Zim Laboratories
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Financials
|
|||
|
5 yr Average ROE
|
62.44 % | 35.94 % | 7.41 % |
|
5yr Avg Net Profit Margin
|
-0.79 % | 17.11 % | 4.15 % |
|
Price to Book
|
3.47 | 5.98 | 1.44 |
|
P/E
|
47.85 | 29.31 | 38.71 |
|
5yr Avg Cash Conversion Cycle
|
32.55 Days | 94.4 Days | 37.07 Days |
|
5yr Average Interest Coverage Ratio
|
2.2 | 17.94 | 3.96 |
|
5yr Avg ROCE
|
25.83 % | 29.15 % | 13.52 % |
|
5yr Avg Operating Profit Margin
|
24.02 % | 16.89 % | 12.21 % |
|
5 yr average Debt to Equity
|
1.25 | 0.34 | 0.39 |
|
5yr CAGR Net Profit
|
n/a | 9.93 % | 10.7 % |
|
5yr Average Return on Assets
|
1.72 % | 15.87 % | 4.02 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
58.16 % | 63.04 % | 33.26 % |
|
Share Pledged by Promoters
|
0.0 | 3.46 % | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
10.36 % | -6.53 % | 0.0 |
|
Change in Mutual Fund Holding (3 Yrs)
|
-3.53 % | 0.0 | 0.0 |
|
Lyka Labs
|
Trident Lifeline
|
Zim Laboratories
|
|---|